Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 10/20 | 0.58 |
| ▸ | GSK3B | P49841 | 7/20 | 0.58 |
| ▸ | TTK | P33981 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | WNT1 | P04628 | 5/20 | 0.42 |
| ▸ | CLK2 | P49760 | 3/20 | 0.42 |
| ▸ | CLK3 | P49761 | 3/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.41 |
| ▸ | PLAU | P00749 | 1/20 | 0.41 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17643975 | 1.00 | DYRK1A (0.58) | DYRK1AGSK3BTTKUSP30MTOR | |
| SCHEMBL29710311 | 0.88 | DYRK1A (0.60) | DYRK1AGSK3BMTORWNT1CLK2 | |
| SCHEMBL29710317 | 0.88 | DYRK1A (0.60) | DYRK1AGSK3BMTORWNT1CLK2 | |
| SCHEMBL17631721 | 0.88 | DYRK1A (0.60) | DYRK1AGSK3BMTORWNT1CLK2 | |
| SCHEMBL17631521 | 0.86 | GSK3B (0.59) | DYRK1AGSK3BMTORWNT1ABL1 | |
| SCHEMBL20828520 | 0.82 | GRIN2B (0.47) | DYRK1AGSK3BNAMPT | |
| SCHEMBL17631620 | 0.82 | MTOR (0.51) | DYRK1AGSK3BTTKUSP30MTOR | |
| SCHEMBL25303717 | 0.81 | GSK3B (0.54) | DYRK1AGSK3BABL1LCK | |
| SCHEMBL30381612 | 0.81 | GSK3B (0.54) | DYRK1AGSK3BABL1LCK | |
| SCHEMBL4302469 | 0.81 | GSK3B (0.61) | DYRK1AGSK3BMTORWNT1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11993595-B2 | Compounds | MISSION THERAPEUTICS LIMITED (GB) | 2024-05-28 | — | — | US | disclosed |
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-11472798-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11472798-B2 | Compounds | UCHL1, UCHL3, UCHL5 | DYRK1A 1569/4885GSK3B 1482/4885TTK 3520/4885 |
| US-11993595-B2 | Compounds | UCHL1, UCHL3, UCHL5 | DYRK1A 1569/4885GSK3B 1482/4885TTK 3520/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | DYRK1A 1587/4885GSK3B 1950/4885TTK 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.